Literature DB >> 15223613

Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression.

Rosaria Alba Merendino1, Giuseppe Di Pasquale, Filippo De Luca, Laura Di Pasquale, Edoardo Ferlazzo, Gabriella Martino, Maura Carmela Palumbo, Fortunato Morabito, Sebastiano Gangemi.   

Abstract

Moderate-severe depression (MSD) is linked to overexpression of proinflammatory cytokines and chemokines. Fractalkine (FKN) and macrophage inflammatory protein-1 alpha (MIP-1alpha) are, respectively, members of CX3C and C-C chemokines, and both are involved in recruiting and activating mononuclear phagocytes in the central nervous system. We analysed the presence of FKN and MIP-1alpha in sera of untreated MSD patients and healthy donors. High FKN levels were observed in all MSD patients as compared with values only detectable in 26% of healthy donors. MIP-1alpha was measurable in 20% of patients, while no healthy donors showed detectable chemokine levels. In conclusion, we describe a previously unknown involvement of FKN in the pathogenesis of MSD, suggesting that FKN may represent a target for a specific immune therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223613      PMCID: PMC1781561          DOI: 10.1080/09511920410001713484

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  5 in total

1.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 2.  Characterization of chemokines and their receptors in the central nervous system: physiopathological implications.

Authors:  Adriana Bajetto; Rudy Bonavia; Simone Barbero; Gennaro Schettini
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

3.  Immune and hormonal activity in adults suffering from depression.

Authors:  S O V Nunes; E M V Reiche; H K Morimoto; T Matsuo; E N Itano; E C D Xavier; C M Yamashita; V R Vieira; A V Menoli; S S Silva; F B Costa; F V Reiche; F L V Silva; M S Kaminami
Journal:  Braz J Med Biol Res       Date:  2002-05       Impact factor: 2.590

4.  The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men.

Authors:  Edward C Suarez; Ranga R Krishnan; James G Lewis
Journal:  Psychosom Med       Date:  2003 May-Jun       Impact factor: 4.312

5.  Interleukin-18 and CD30 serum levels in patients with moderate-severe depression.

Authors:  Rosaria Alba Merendino; Antonio Enrico Di Rosa; Giuseppe Di Pasquale; Paola Lucia Minciullo; Carmela Mangraviti; Antonella Costantino; Antonella Ruello; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2002-08       Impact factor: 4.711

  5 in total
  13 in total

1.  Central neuroimmune activity and depressive-like behavior in response to repeated maternal separation and injection of LPS.

Authors:  Michael B Hennessy; Terrence Deak; Joshua D Sensenbaugh; Darci M Gallimore; Alexis M Garybush; Jamie E Mondello; Patricia A Schiml
Journal:  Physiol Behav       Date:  2018-11-30

2.  Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic Mouse Model of High Methamphetamine Intake.

Authors:  Marilyn Huckans; Clare J Wilhelm; Tamara J Phillips; Elaine T Huang; Rebekah Hudson; Jennifer M Loftis
Journal:  Neuropsychobiology       Date:  2018-01-18       Impact factor: 2.328

3.  A meta-analysis of chemokines in major depression.

Authors:  Harris A Eyre; Tracy Air; Alyssa Pradhan; James Johnston; Helen Lavretsky; Michael J Stuart; Bernhard T Baune
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-20       Impact factor: 5.067

4.  Inflammation is increased with anxiety- and depression-like signs in a rat model of spinal cord injury.

Authors:  Sioui Maldonado-Bouchard; Kelsey Peters; Sarah A Woller; Behrouz Madahian; Usef Faghihi; Shivani Patel; Shameena Bake; Michelle A Hook
Journal:  Brain Behav Immun       Date:  2015-08-18       Impact factor: 7.217

5.  Neuropathic pain promotes adaptive changes in gene expression in brain networks involved in stress and depression.

Authors:  Giannina Descalzi; Vasiliki Mitsi; Immanuel Purushothaman; Sevasti Gaspari; Kleopatra Avrampou; Yong-Hwee Eddie Loh; Li Shen; Venetia Zachariou
Journal:  Sci Signal       Date:  2017-03-21       Impact factor: 8.192

6.  Data-driven discovery of mid-pregnancy immune markers associated with maternal lifetime stress: results from an urban pre-birth cohort.

Authors:  Whitney Cowell; Elena Colicino; Alison G Lee; Michelle Bosquet Enlow; Julie D Flom; Cecilia Berin; Robert O Wright; Rosalind J Wright
Journal:  Stress       Date:  2019-11-09       Impact factor: 3.493

Review 7.  A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders.

Authors:  Joanna Ślusarczyk; Ewa Trojan; Jakub Chwastek; Katarzyna Głombik; Agnieszka Basta-Kaim
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 8.  Depression and Cardiovascular Disease: The Viewpoint of Platelets.

Authors:  Patrizia Amadio; Marta Zarà; Leonardo Sandrini; Alessandro Ieraci; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

9.  Chemokine profile in women with moderate to severe anxiety and depression during pregnancy.

Authors:  Ignacio Camacho-Arroyo; Mónica Flores-Ramos; Ismael Mancilla-Herrera; Fausto Moisés Coronel Cruz; Joselin Hernández-Ruiz; Gabriela Pellón Diaz; Blanca Farfán Labonne; María Del Pilar Meza-Rodríguez; Philippe Leff Gelman
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-04       Impact factor: 3.007

10.  High Serum Levels of iNOS and MIP-1α are Associated with Post-Stroke Depression.

Authors:  Xiuli Wang; Cui Fang; Xiaoxi Liu; Wei Wei; Mengfan Zhang; Shuang Chen; Fuping Shi
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-28       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.